The glycosaminoglycans (GAGs) heparin, heparan sulphate and chondroitin 6-sulphate stimulate the rate of urokinase activation of human plasminogen. Kinetic analysis of plasminogen activation demonstrates that heparin, heparan sulphate and chondroitin 6-sulphate increased the catalytic rate (K,.t.) by 5.3-, 3.5-and 2.5-fold respectively. These stimulatory GAGs had no effect on the affinity of urokinase for plasminogen, since the Km of the reaction is unaltered by the GAGs. The GAGs may enhance the rate of plasminogen activation through an interaction with the catalytic domain of the urokinase, with dissociation constants of approx. 30 nm. Additionally, the lipoproteins, lipoprotein (a) [Lp(a)] and low-density lipoprotein (LDL) inhibit heparin and heparan sulphate stimulation of plasmin formation. Lp(a) is a competitive inhibitor (K,, 20 nM) and LDL is a mixed inhibitor of heparin-enhanced urokinase-mediated plasminogen activation (Kc 24 nm and Kiu 60 nM). These inhibition constants correlate with physiological concentrations of these lipoproteins. These data suggest that these GAGs and lipoproteins may play an important role in vivo in regulating urokinase-mediated plasmin formation.
INTRODUCTION
Plasmin is the principal enzyme of fibrinolysis. Like other coagulation and fibrinolytic pathway enzymes, plasmin is secreted as an inactive zymogen, plasminogen. The physiological activation ofplasminogen is mediated by tissue-type plasminogen activator (t-PA) and urokinase (Collen, 1980; Castellino, 1981) . Activation of the fibrinolytic system is regulated by surface components of both macrophage and endothelial cells (Hajjar et al., 1987; Miles & Plow, 1987) . Several other vascular components can also regulate plasminogen activation, including extracellular matrix (Silverstein et al., 1985; Stack et al., 1990) , Cl-ions (Urano et al., 1987) , a2-antiplasmin (Lijnen & Collen, 1986) , plasminogen activator inhibitor-I (Sprengers & Kluft, 1987) , lipoprotein (a) [Lp(a)] and heparin (Markwardt & Klocking, 1977) .
The glycosaminoglycan (GAG) heparin enhances the rate of plasmin formation catalysed by both t-PA and urokinase (Andrade-Gordon & Strickland, 1986; Paques et al., 1986) . Heparin is found on the vascular surface and basement membrane, where it exerts a well-characterized anticoagulant effect (Marcum & Rosenberg, 1984 Marcum et al., 1986) . In addition, Markwardt & Klocking (1977) proposed that this GAG may also increase fibrinolytic activity. Several recent studies suggest that heparin increases the rate of both t-PA-and urokinase-mediated plasmin formation (Andrade-Gordon & Strickland, 1986; Paques et al., 1986) . Further studies have demonstrated that the t-PA N-terminal 'finger' domain is involved in the heparin enhancement of plasminogen activation (Stein et al., 1989; .
Since urokinase does not contain a 'finger' domain, the heparin interaction with this enzyme must differ from the interaction between t-PA and heparin. In addition, Rydzewski et al. (1989) demonstrated that the GAG, chondroitin 6-sulphate, increased the rate of urokinase-catalysed plasmin formation, but had no effect on t-PA-mediated plasminogen activation (Andrade-Gordon & Strickland, 1986; . This further suggests that interaction between urokinase and GAGs is markedly different from the t-PA-heparin interaction. This study describes a kinetic analysis of the effects of heparin, heparan sulphate and chondroitin 6-sulphate on urokinasemediated plasminogen activation. We have also determined the effect of two related lipoproteins, Lp(a) and low-density lipoprotein (LDL), on this GAG-enhanced urokinase-mediated plasmin formation.
MATERIALS AND METHODS

Reagents
The plasmin substrate D-Val-L-Leu-L-Lys p-nitroanilide dihydrochloride (VLK-NH-Np or S-2251) and the urokinase substrate D-Ile-L-Pro-L-Arg p-nitroanilide dihydrochloride (IPR-NH-Np or S-2288) were purchased from Helena Laboratories (Beaumont, TX, U.S.A.). All other reagents were of the best grade commercially available.
Glycosaminoglycans
GAGs 
Proteins
Human plasminogen glycoform 2 was isolated by affinity chromatography as previously described by Deutsch & Mertz (1970) and modified by Brockway & Castellino (1972) and Gonzalez-Gronow & Robbins (1984) . High-molecular-mass twochain urokinase and low-molecular-mass two-chain urokinase were purchased from Calbiochem (San Diego, CA, U.S.A.).
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Human fibrinogen was obtained from Kabivitrum (Stockholm, Sweden) and rendered plasminogen-free on lysine-Sepharose. Lp(a) was purified as previously described by Edelberg et al. (1989) . LDL was obtained from Sigma Chemical Co., and purity was confirmed by SDS/PAGE as previously described .
Determination of heparin, heparan sulphate and chondroitin 6-sulphate kinetic activation constants Plasminogen was activated with urokinase in a manner analogous to activation by t-PA . Briefly, various concentrations of plasminogen were incubated in 50 mmTris/HCl buffer, pH 7.4, with 0.5 nM-urokinase in the presence of the plasmin substrate VLK-NH-Np (300 /,M) and increasing concentrations of heparin, heparan sulphate, dermatan sulphate, keratan sulphate, chondroitin, chondroitin 4-sulphate, chondroitin 6-sulphate or fibrinogen. Similar studies with the low-molecular-mass enzyme were also performed. All kinetic analyses were performed at least in triplicate. The initial rate of plasminogen activation (Vi) was determined by using the equation:
where b is the initial velocity of substrate hydrolysis derived from a plot of instantaneous rate of substrate cleavage versus time, KE is the apparent Michaelis constant of VLK-NH-Np hydrolysis by plasmin (0.3 mM), ke is the catalytic rate constant for plasmin hydrolysis of VLK-NH-Np determined for fully activated plasminogen 2 (2.3 x 103 M/mol of plasmin per s) and e is the molar absorption coefficient of the hydrolysed substrate at 405 nm (104 M-l cm-l) (Erlanger et al., 1961) . The kinetic constants for plasminogen activation were determined by double-reciprocal plots of initial rates versus plasminogen concentration in the absence of any GAGs. In the presence of GAGs, the kinetic activation constants were determined by using the equation: (Dixon & Webb, 1979) . From a double-reciprocal plot of initial rates of plasmin formation versus plasminogen concentration in the presence of increasing concentration of GAGs, the change (A) from control in both abscissa intercepts and slopes were determined for each concentration of GAG (Dixon & Webb, 1979) . The constants a, , and Ka were calculated from a double-reciprocal plot of A intercept and slope values versus the GAG concentration. In addition, the effect of heparin on urokinase amidolytic activity was determined. Briefly, 0.5 nmurokinase was incubated with IPR-NH-Np (300 /UM) in the presence of increasing heparin concentration, and the initial rate of substrate hydrolysis measured.
Determination of Lp(a) and LDL kinetic inhibition constants
Plasminogen was activated in a buffer containing 85 nmheparin, as described above, in the presence of increasing concentrations of Lp(a) or LDL. All kinetic analyses were performed at least in triplicate. The initial rate of plasmin formation was determined as described above. The inhibition constants were determined by using the equation: [S] in which KI. and K,. represent the competitive and uncompetitive inhibition constants respectively (Dixon, 1954; Knight, 1986) . Similar experiments were also performed in the absence of any GAGs, and in the presence of heparin, chondroitin 6-sulphate and fibrinogen. In addition, the effect oflipoproteins on urokinase amidolytic activity was determined, as described previously for t-PA activity . Briefly, 0.5 nM-urokinase was incubated with IPR-NH-Np (300 /SM) in the presence of 85 nM-heparin and increasing concentrations of Lp(a) and LDL, and the initial rate of substrate hydrolysis was measured. (Lucas et al., 1983; Watahiki et al., 1987; Homanberg & Wait, 1990 ). The addition of heparin, heparan sulphate and chondroitin 6-sulphate to the reaction (Figs. la, 2a and 3a respectively) increased the rate of plasminogen activation by 5.3-. 3.5-and 2.5-fold respectively. The replots of the data (Figs. lb, 2b and 3b) increases were 10-and 3-fold respectively. Urokinase amidolytic activity was independent of the concentration of heparin present, consistent with previous observations (Andrade-Gordon & Strickland, 1986; Paques et al., 1986; Rydzewski et al., 1989) . We have observed a similar result with t-PA (Figs. 4a and 5a ). The Dixon plot in Fig.   4 (a) demonstrates that increasing concentrations of Lp(a) inhibit plasmin formation. The replot of the data (Fig. 4b) demonstrates that Lp(a) is a competitive inhibitor with a K1C of 20 nm. Fig. 5(a) demonstrates that LDL also decreased the rate of plasminogen activation. The replot (Fig. 5b) 
RESULTS
DISCUSSION
Plasminogen activation is an important component of several physiological and pathophysiological processes. In addition to fibrinolysis, plasmin is involved in tissue remodelling, ovulation, neuronal development, tumorigenesis and metastasis (Dano et al., 1985) . Whereas t-PA is active primarily in the vasculature, urokinase is active in both the vasculature and the extravascular space (Dano et al., 1985) . Regulation of plasmin formation by plasminogen activators is mediated by several proteins, including fibrin, fibrinogen (Hoyalerts et al., 1982; Ranby et al., 1982; Nieuwenhuizen et al., 1983; De Serrano et al., 1989) , collagen, laminin (Stack et al., 1990) , thrombospondin, histidine-rich glycoprotein (Silverstein et al., 1985) , plasminogen activator inhibitor-I (Sprengers & Kluft, 1987) , ac2-antiplasmin (Wiman & Collen, 1978) and Lp(a) , as well as by several non-protein components including macrophage-and epithelial-cell binding sites (Hajar et al., 1987; Miles & Plow, 1987) and GAGs (Andrade-Gordon & Strickland, 1986; Paques et al., 1986; . The focus of recent work has been on the regulation of t-PA by these components, with less research directed towards understanding the regulation of urokinase.
Several recent studies have examined the role of heparin in the enhancement of plasminogen activation by both t-PA and urokinase. Heparin increases the rate of plasmin generation by t-PA and urokinase by 5-30-fold and 3-15-fold respectively (Andrade-Gordon & Strickland, 1986; Paques et al., 1986; Fears, 1988; Rydzewski et al., 1989; ). In addition, Fears (1988) reported a stimulation in the rate of urokinase-mediated Glu-plasminogen activation by heparin in the presence of fibrinogen. The above studies demonstrated that the heparin enhancement of t-PA function is due to an increase in the catalytic activity of the enzyme, but did not fully characterize the mechanism of the stimulation of urokinase activity.
Kinetic studies described here demonstrate that heparin stimulates urokinase-mediated plasminogen activation. Furthermore, these experiments demonstrate that heparan sulphate, which is structurally similar to, but less sulphated than, heparin, also increases the rate of plasminogen activation by urokinase. These results are similar to previously reported stimulation of t-PA-catalysed plasminogen activation by heparin and heparan sulphate . In contrast with t-PA, urokinase activation of plasminogen is also enhanced by chondroitin 6-sulphate, in good agreement with data of Rydzewski et al. (1989) .
Though the GAG enhancement of both t-PA-and urokinasemediated plasmin formation is due to an increase in the catalytic rate of the enzymes, the interaction of the GAGs may be markedly different with t-PA and urokinase. Experiments with t-PA, including deletion mutation (Stein et al., 1989) and kinetic modelling studies , suggest that heparin enhances the catalytic rate of t-PA by binding to the 'finger' domain in the N-terminal region of the activator. The interaction of urokinase with heparin, heparan sulphate and chondroitin 6-sulphate must involve a different binding site, since urokinase lacks a 'finger' domain. In addition, the Ka of GAG binding to urokinase (approx. 30 nM) is 30-fold greater than that of the binding of heparin to t-PA.
Our data demonstrate that the stimulatory GAGs, heparin, heparan sulphate and chondroitin 6-sulphate, enhance the rate Vol. 276 of plasmin generation by increasing the k,t8 of the urokinase, but they do not affect the Km of the activation reaction. Furthermore, the activation constants (Ka) of these GAGs for urokinase are similar (25 nm compared with 35 nM), suggesting that the urokinase activity may be enhanced by a common structural feature of the three stimulatory GAGs. These GAGs share two structural similarities, a carboxy group and a sulphate group, at the 6-positions in the altering residues in the disaccharides. GAGs lacking either of these structures (e.g. chondroitin 4-sulphate, dermatan sulphate or keratan sulphate) do not enhance the urokinase-mediated plasminogen activation. However, decarboxylation of the heparin and chondroitin 6-sulphate did not affect the rate of plasmin generation, indicating that the 6-position sulphate group may be critical.
To probe the mechanism of GAG interaction with urokinase, we determined the effect of GAGs on the low-molecular-mass form of the enzyme, which contains only the catalytic domain. Both heparin and chondroitin 6-sulphate increased the rate of plasminogen activation mediated by this enzyme. These results are consistent with studies by Soeda et al. (1987 Soeda et al. ( , 1989 that suggest that heparin interacts with the isolated catalytic domain of several fibrinolytic serine proteinases. They demonstrated that heparin binds to the catalytic domain of t-PA and stimulates the activity of the proteinase by 3-fold, as compared with the 5-25-fold stimulation measured with the intact enzyme (AndradeGordon & Strickland, 1986; . However, Soeda et al. (1989) demonstrated that heparin binds to the plasminogen catalytic domain with higher affinity than it binds to native Glu-or Lys-plasminogen. The interaction between GAGs and serine proteinases extends to other proteinases that have only catalytic domains. Marossy (1981) demonstrated that heparin, heparan sulphate and chondroitin 6-sulphate had strong ionic interactions with chymotrypsin and elastase-like enzymes.
The heparin enhancement of urokinase-mediated plasminogen activation may be involved in several physiological and pathophysiological processes. For example, urokinase secreted from endothelial cells (Kjaeldgaard et al., 1986 ) may bind heparin and heparan sulphate on the endothelial surface (Marcum & Rosenberg, 1984 Marcum et al., 1986) , thereby increasing the local concentration of the activator, as well as enhancing the catalytic rate of plasminogen activation. In addition, heparin produced by embryonic fibroblasts (Woods et al., 1985) may enhance plasminogen activation to stimulate tissue remodelling .
Plasmin generation and urokinase synthesis correlate with cell migration and tissue remodelling in ovulation (Beers, 1975; Wang & Leung, 1983; Canipari & Strickland, 1985) . Strickland & Beers (1976) proposed that the plasminogen activators are secreted into the follicular fluid, where they convert plasminogen into plasmin, thus initiating the sequence of events that results in follicular rupture. Both heparin and chondroitin 6-sulphate are secreted into ovarian follicles (Mueller et al., 1978; Gebauer et al., 1978; Ax & Ryan, 1979; Yanagishita et al., 1979; Grimek & Ax, 1982) . Thus the stimulatory GAGs may regulate the activity of the urokinase in the developing oocytes and thereby regulate the rupture of follicles.
The activation of plasminogen also occurs during cell migration and tissue remodelling which accompany tumorigenesis. Several solid tumours secrete urokinase (Astedt & Holmberg, 1976; Markus et al., 1980; Camiolo et al., 1981; Evers et al., 1982) . In addition, several tumour cells produce heparin and heparan sulphate (Hassell et al., 1985; Furwara et al., 1984; Bouiziges et al., 1990) , suggesting that the production of GAGs may increase the ability of these tumours to metastasize (Reich et al., 1988) .
The heparin and heparan sulphate enhancement of urokinase-mediated plasminogen activation is regulated by lipoproteins in a manner similar to the regulation of heparin-enhanced t-PAmediated plasminogen activation. Lp(a) contains an apoprotein (a) subunit that has a high degree of sequence similarity to plasminogen. Previous studies demonstrated that Lp(a) acts as a plasminogen analogue by competing for plasminogen-binding sites on cell surfaces, fibrin and heparin Miles et al., 1989; Hajjar et al., 1989; Harpel et al., 1989; . Lp(a) inhibits plasminogen activation by t-PA, but only in the presence of fibrinogen and heparin. In the studies described here, Lp(a) inhibits plasminogen activation by urokinase only in the presence of heparin or heparan sulphate, but not in the presence of chondroitin 6-sulphate or fibrinogen, or in the absence of an enhancer. Lp(a) inhibits by competing with plasminogen for aocess to the enhancer-bound urokinase, but does not occupy the active site directly. As a competitive inhibitor, Lp(a) may block the access of plasminogen to the heparin-and heparan sulphatebound urokinase, without competing with urokinase for its binding site on the heparin or heparan sulphate, which kinetically would indicate an uncompetitive inhibitor. This suggests that Lp(a) binds to the heparin and heparan sulphate at a site other than where the urokinase binds. The Lp(a) inhibition constant of 20 nm correlates with a physiological plasma concentration of 8 mg/dl (Rhoads et al., 1986; Dahlen et al., 1986; Murai et al., 1986) , suggesting that Lp(a) may regulate the production of plasmin by heparin-enhanced urokinase in the plasma during fibrinolysis.
Our data also indicate that LDL is a mixed inhibitor of urokinase-mediated plasminogen activation, but only in the presence of heparin and heparan sulphate. Similarly to the inhibition observed with Lp(a), LDL blocks the access of plasminogen to the GAG-enhanced urokinase, but also decreases the catalytic rate of the enzyme. This suggests that LDL may bind to a site other than that where urokinase binds to the heparin and may block access of plasminogen to urokinase, as well as to the site at which urokinase binds to the heparin. The resultant effect is to decrease the enhancement in the catalytic rate of the activator. Like Lp(a), fthe LDL inhibition constants of 24 nm and 64 nm correlate with concentrations below the normal plasma levels of this lipoprotein (9 and 24 mg/dl respectively) (Rhoads et al., 1986) . This suggests that both Lp(a) and LDL may be regulators of heparin-enhanced urokinase-mediated fibrinolysis.
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